Search Results - "Lawson, Mandy"

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists by Toy, Weiyi, Weir, Hazel, Razavi, Pedram, Lawson, Mandy, Goeppert, Anne U, Mazzola, Anne Marie, Smith, Aaron, Wilson, Joanne, Morrow, Christopher, Wong, Wai Lin, De Stanchina, Elisa, Carlson, Kathryn E, Martin, Teresa S, Uddin, Sharmeen, Li, Zhiqiang, Fanning, Sean, Katzenellenbogen, John A, Greene, Geoffrey, Baselga, José, Chandarlapaty, Sarat

“…Recent studies have identified somatic mutations in patients with metastatic breast cancer and found some of them to promote estrogen-independent activation of…”
Get more information

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer by Michaloglou, Chrysiis, Crafter, Claire, Siersbaek, Rasmus, Delpuech, Oona, Curwen, Jon O, Carnevalli, Larissa S, Staniszewska, Anna D, Polanska, Urszula M, Cheraghchi-Bashi, Azadeh, Lawson, Mandy, Chernukhin, Igor, McEwen, Robert, Carroll, Jason S, Cosulich, Sabina C

“…The cyclin dependent kinase (CDK)-retinoblastoma (RB)-E2F pathway plays a critical role in the control of cell cycle in estrogen receptor-positive (ER ) breast…”
Get full text

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC by Hayhow, Thomas G., Williamson, Beth, Lawson, Mandy, Cureton, Natalie, Braybrooke, Erin L., Campbell, Andrew, Carbajo, Rodrigo J., Cheraghchi-Bashi, Azadeh, Chiarparin, Elisabetta, Diène, Coura R., Fallan, Charlene, Fisher, David I., Goldberg, Frederick W., Hopcroft, Lorna, Hopcroft, Philip, Jackson, Anne, Kettle, Jason G., Klinowska, Teresa, Künzel, Ulrike, Lamont, Gillian, Lewis, Hilary J., Maglennon, Gareth, Martin, Scott, Gutierrez, Pablo Morentin, Morrow, Christopher J., Nikolaou, Myria, Nissink, J. Willem M., O’Shea, Patrick, Polanski, Radoslaw, Schade, Markus, Scott, James S., Smith, Aaron, Weber, Judith, Wilson, Joanne, Yang, Bin, Crafter, Claire

“…Targeting the estrogen receptor alpha (ERα) pathway is validated in the clinic as an effective means to treat ER+ breast cancers. Here we present the…”
Get full text

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models by Weir, Hazel M, Bradbury, Robert H, Lawson, Mandy, Rabow, Alfred A, Buttar, David, Callis, Rowena J, Curwen, Jon O, de Almeida, Camila, Ballard, Peter, Hulse, Michael, Donald, Craig S, Feron, Lyman J L, Karoutchi, Galith, MacFaul, Philip, Moss, Thomas, Norman, Richard A, Pearson, Stuart E, Tonge, Michael, Davies, Gareth, Walker, Graeme E, Wilson, Zena, Rowlinson, Rachel, Powell, Steve, Sadler, Claire, Richmond, Graham, Ladd, Brendon, Pazolli, Ermira, Mazzola, Anne Marie, D'Cruz, Celina, De Savi, Chris

“…Fulvestrant is an estrogen receptor (ER) antagonist administered to breast cancer patients by monthly intramuscular injection. Given its present limitations of…”
Get full text

Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist by Scott, James S, Moss, Thomas A, Balazs, Amber, Barlaam, Bernard, Breed, Jason, Carbajo, Rodrigo J, Chiarparin, Elisabetta, Davey, Paul R. J, Delpuech, Oona, Fawell, Stephen, Fisher, David I, Gagrica, Sladjana, Gangl, Eric T, Grebe, Tyler, Greenwood, Ryan D, Hande, Sudhir, Hatoum-Mokdad, Holia, Herlihy, Kara, Hughes, Samantha, Hunt, Thomas A, Huynh, Hoan, Janbon, Sophie L. M, Johnson, Tony, Kavanagh, Stefan, Klinowska, Teresa, Lawson, Mandy, Lister, Andrew S, Marden, Stacey, McGinnity, Dermot F, Morrow, Christopher J, Nissink, J. Willem M, O’Donovan, Daniel H, Peng, Bo, Polanski, Radoslaw, Stead, Darren S, Stokes, Stephen, Thakur, Kumar, Throner, Scott R, Tucker, Michael J, Varnes, Jeffrey, Wang, Haixia, Wilson, David M, Wu, Dedong, Wu, Ye, Yang, Bin, Yang, Wenzhan

“…Herein we report the optimization of a series of tricyclic indazoles as selective estrogen receptor degraders (SERD) and antagonists for the treatment of ER+…”
Get full text

Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer by Harrod, Alison, Lai, Chun-Fui, Goldsbrough, Isabella, Simmons, Georgia M., Oppermans, Natasha, Santos, Daniela B., Győrffy, Balazs, Allsopp, Rebecca C., Toghill, Bradley J., Balachandran, Kirsty, Lawson, Mandy, Morrow, Christopher J., Surakala, Manasa, Carnevalli, Larissa S., Zhang, Pei, Guttery, David S., Shaw, Jacqueline A., Coombes, R. Charles, Buluwela, Lakjaya, Ali, Simak

“…Mutations in the estrogen receptor (ESR1) gene are common in ER-positive breast cancer patients who progress on endocrine therapies. Most mutations localise to…”
Get full text

Abstract 4369: Preclinical mechanistic PK/PD-efficacy modeling for AZD9833, a novel next generation oral SERD, to support dose selection during early clinical development by Gutierrez, Pablo Morentin, Morrow, Christopher, Cureton, Natalie, Lawson, Mandy, Trueman, Dawn, Gangl, Eric, Wilson, Joanne, Smith, Aaron, Scott, James, Klinowska, Teresa

“…Abstract Objectives: The estrogen receptor alpha (ERα) is highly expressed in breast cancers and is a clinically validated target in oncology. AZD9833 is a…”
Get full text

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance by Lawson, Mandy, Cureton, Natalie, Ros, Susana, Cheraghchi-Bashi, Azadeh, Urosevic, Jelena, D'Arcy, Sophie, Delpuech, Oona, DuPont, Michelle, Fisher, David I, Gangl, Eric T, Lewis, Hilary, Trueman, Dawn, Wali, Neha, Williamson, Stuart C, Moss, Jennifer, Montaudon, Elodie, Derrien, Heloise, Marangoni, Elisabetta, Miragaia, Ricardo J, Gagrica, Sladjana, Morentin-Gutierrez, Pablo, Moss, Thomas A, Maglennon, Gareth, Sutton, Daniel, Polanski, Radoslaw, Rosen, Alan, Cairns, Jonathan, Zhang, Pei, Sánchez-Guixé, Mònica, Serra, Violeta, Critchlow, Susan E, Scott, James S, Lindemann, Justin P O, Barry, Simon T, Klinowska, Teresa, Morrow, Christopher J, Carnevalli, Larissa

“…Oral selective estrogen receptor degraders (SERD) could become the backbone of endocrine therapy (ET) for estrogen receptor-positive (ER+) breast cancer, as…”
Get full text

Abstract 4379: Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant by Lawson, Mandy, Cureton, Natalie, DuPont, Michelle, Delpuech, Oona, Trueman, Dawn, Zhang, Pei, Cheraghchi-Bashi-Astaneh, Azadeh, Gagrica, Sladjana, Maglennon, Gareth, Sutton, Daniel, Zhang, Bairu, Cairns, Jonathan, Scott, Jamie, Klinowska, Teresa, Morrow, Christopher J.

“…Abstract Anti-hormonal therapy has been the mainstay treatment for estrogen receptor (ER) +ve breast cancer for >40 years. The selective ER degrader (SERD)…”
Get full text

Abstract 5674: Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD) by Scott, James S., Moss, Thomas, Stokes, Steve, Nissink, Willem M., Morrow, Christopher J., Lawson, Mandy, Cureton, Natalie, Gangl, Eric, Gutierrez, Pablo Morentin, Mather, Richard, Lindemann, Justin P., Sykes, Andrew, Fisher, David, Polanski, Radoslaw, Carroll, Danielle, Twomey, Aisling Barton, Klinowska, Teresa

“…Abstract The estrogen receptor alpha (ERα) is expressed in >70% of breast cancers and is a clinically validated target in oncology. Anti-hormonal therapies…”
Get full text

Tricyclic IndazolesA Novel Class of Selective Estrogen Receptor Degrader Antagonists by Scott, James S, Bailey, Andrew, Buttar, David, Carbajo, Rodrigo J, Curwen, Jon, Davey, Paul R. J, Davies, Robert D. M, Degorce, Sébastien L, Donald, Craig, Gangl, Eric, Greenwood, Ryan, Groombridge, Sam D, Johnson, Tony, Lamont, Scott, Lawson, Mandy, Lister, Andrew, Morrow, Christopher J, Moss, Thomas A, Pink, Jennifer H, Polanski, Radoslaw

“…Herein, we report the identification and synthesis of a series of tricyclic indazoles as a novel class of selective estrogen receptor degrader antagonists…”
Get full text

Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel by Hancox, Urs, Cosulich, Sabina, Hanson, Lyndsey, Trigwell, Cath, Lenaghan, Carol, Ellston, Rebecca, Dry, Hannah, Crafter, Claire, Barlaam, Bernard, Fitzek, Martina, Smith, Paul D, Ogilvie, Donald, D'Cruz, Celina, Castriotta, Lillian, Wedge, Stephen R, Ward, Lara, Powell, Steve, Lawson, Mandy, Davies, Barry R, Harrington, Elizabeth A, Foster, Emily, Cumberbatch, Marie, Green, Stephen, Barry, Simon T

“…Loss of PTEN protein results in upregulation of the PI3K/AKT pathway, which appears dependent on the PI3Kβ isoform. Inhibitors of PI3Kβ have potential to…”
Get full text

Abstract P6-04-15: Oral selective estrogen receptor degrader AZD9496 demonstrated preclinical model specific differences to fulvestrant in estrogen receptor degradation, agonism and anti-tumour effects by Lawson, Mandy, Cureton, Natalie, Delpuech, Oona, Zhang, Pei, Cheraghchi-Bashi-Astaneh, Azadeh, Gagrica, Sladjana, Trueman, Dawn, Maglennon, Gareth, Sutton, Daniel, Zhang, Bairu, Cairns, Jonathan, Klinowska, Teresa, Morrow, Christopher J

“…Abstract Anti-hormonal therapy has been the mainstay for the treatment of estrogen receptor (ER) positive breast cancer for over 40 years. The selective ER…”
Get full text

Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists by Scott, James S., Stead, Darren, Barlaam, Bernard, Breed, Jason, Carbajo, Rodrigo J., Chiarparin, Elisabetta, Cureton, Natalie, Davey, Paul R. J., Fisher, David I., Gangl, Eric T., Grebe, Tyler, Greenwood, Ryan D., Hande, Sudhir, Hatoum-Mokdad, Holia, Hughes, Samantha J., Hunt, Thomas A., Johnson, Tony, Kavanagh, Stefan L., Klinowska, Teresa C. M., Larner, Carrie J. B., Lawson, Mandy, Lister, Andrew S., Longmire, David, Marden, Stacey, McGuire, Thomas M., McMillan, Caroline, McMurray, Lindsay, Morrow, Christopher J., Nissink, J. Willem M., Moss, Thomas A., O’Donovan, Daniel H., Polanski, Radoslaw, Stokes, Stephen, Thakur, Kumar, Trueman, Dawn, Truman, Caroline, Tucker, Michael J., Wang, Haixia, Whalley, Nicky, Wu, Dedong, Wu, Ye, Yang, Bin, Yang, Wenzhan

“…Herein, we report the optimization of a meta-substituted series of selective estrogen receptor degrader (SERD) antagonists for the treatment of ER+ breast…”
Get full text

Abstract PD10-04: PD10-04 Combination of the next generation oral SERD camizestrant (AZD9833) with CDK4/6 and mTOR/AKT inhibitors delivers robust efficacy in a broad range of ER+ breast tumors by Carnevalli, Larissa, Ros, Susana, Urosevic, Jelena, Cureton, Natalie, Darcy, Sophie, Lawson, Mandy, Williamson, Stuart, Gutierrez, Pablo Morentin, Bashi, Azadeh, Moss, Jennifer, Morrow, Christopher, Simon, Barry, Klinowska, Teresa

“…Abstract Next-generation oral selective estrogen receptor degraders (ngSERDs) are aiming to become the backbone endocrine therapy (ET) for patients with…”
Get full text

Abstract P3-07-13: The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor α by Morrow, Christopher, Carnevalli, Larissa, Baird, Richard D., Brier, Tim, Ciardullo, Carmela, Cureton, Natalie, Lawson, Mandy, McEwen, Robert, Nikolaou, Myria, Armstrong, Anne, Bermejo, Begoña, Calvo, Emiliano, Ciruelos, Eva, Garcia-Corbacho, Javier, Hamilton, Erika, Incorvati, Jason, Kabos, Peter, Oliveira, Mafalda, Patel, Manish R, Ruiz-Borregó, Manuel, Turner, Nicholas, Twelves, Chris, Vaklavas, Christos, Carroll, Danielle, Ching, Steven, Cvetesic, Nevena, DuPont, Michelle, Gibbons, Lisa, Mathewson, Alastair, Maudsley, Rhiannon, Gutierrez, Pablo Morentin, Reddy, Avinash, Rodriguez-Canales, Jaime, Ros, Susana, Sudhan, Dhivya, Sykes, Andy, Whitson, David, Klinowska, Teresa, Lindemann, Justin

“…Abstract Endocrine therapy forms the backbone treatment for patients with estrogen receptor (ER) positive tumors in both the adjuvant and metastatic setting…”
Get full text

Hit-to-Lead studies: The discovery of potent adamantane amide P2X 7 receptor antagonists by Baxter, Andrew, Bent, Janice, Bowers, Keith, Braddock, Martin, Brough, Steve, Fagura, Malbinder, Lawson, Mandy, McInally, Tom, Mortimore, Mike, Robertson, Mark, Weaver, Richard, Webborn, Peter

“…A Hit-to-Lead optimisation programme was carried out on the adamantane high throughput screening hit 1 resulting in the discovery of a number of potent P2X 7…”
Get full text

Abstract DDT01-03: Discovery and pre-clinical pharmacology of AZD9496: An oral, selective estrogen receptor down-regulator (SERD) by Weir, Hazel, Lawson, Mandy, Callis, Rowena, Hulse, Michael, Tonge, Michael, Davies, Gareth, Walker, Graeme, Rowlinson, Rachel, Curwen, Jon, Wilson, Zena, Powell, Steve, Bradbury, Robert, Rabow, Alfred, Donald, Craig, Buttar, David, Norman, Richard, de Almeida, Camila, Ballard, Peter, Currie, Gordon, Andrews, David, Richmond, Graham, Mazzola, Anne Marie, Pazolli, Ermira, Ladd, Brendon, D'Cruz, Celina, De Savi, Chris

“…Abstract With over 70% of breast cancers expressing estrogen receptor alpha protein (ERα), treatment with either anti-hormonal therapies that directly block…”
Get full text

Discovery of Potent and Selective Adamantane-Based Small-Molecule P2X 7 Receptor Antagonists/Interleukin-1β Inhibitors by Furber, Mark, Alcaraz, Lilian, Bent, Janice E., Beyerbach, Armin, Bowers, Keith, Braddock, Martin, Caffrey, Moya V., Cladingboel, David, Collington, John, Donald, David K., Fagura, Malbinder, Ince, Frank, Kinchin, Elizabeth C., Laurent, Celine, Lawson, Mandy, Luker, Timothy J., Mortimore, Michael M. P., Pimm, Austen D., Riley, Robert J., Roberts, Nicola, Robertson, Mark, Theaker, Jill, Thorne, Philip V., Weaver, Richard, Webborn, Peter, Willis, Paul

Get full text

Design driven HtL: The discovery and synthesis of new high efficacy β 2 -agonists by Stocks, Michael J., Alcaraz, Lilian, Bailey, Andrew, Bonnert, Roger, Cadogan, Elaine, Christie, Jadeen, Connolly, Stephen, Cook, Anthony, Fisher, Adrian, Flaherty, Alice, Hill, Stephen, Humphries, Alexander, Ingall, Anthony, Jordan, Stephen, Lawson, Mandy, Mullen, Alex, Nicholls, David, Paine, Stuart, Pairaudeau, Garry, St-Gallay, Stephen, Young, Alan

Get full text